PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Bradley J. Monk, MD, FACS, FACOG - Optimizing Precision Medicine in Ovarian Cancer: Expert Insights on Clinical Implications of PARP Inhibitor Therapy and Companion Diagnostics
Go online to PeerView.com/QYX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of PARP inhibitors and precise selection of patients using companion diagnostics have improved outcomes for patients with advanced ovarian cancer and provided new opportunities for oncologists to individualize care. In this activity, based on a recent live webcast, a panel of leading experts discuss the rationale behind the use of PARP inhibition in ovarian cancer and how these agents and their companion diagnostics can be used in clinical practice in a variety of settings. Using case vignettes, the experts address real-world applications of the latest research, including how to prevent and manage adverse events associated with the use of PARP inhibitors and determine which patients may benefit from enrollment in clinical trials testing these agents alone or in combination with other treatments. Upon completion of this activity, participants should be better able to: Review the rationale of PARP inhibitors targeting DNA repair pathway mutations as well as their validated clinical evidence in ovarian cancer, Employ PARP inhibitor therapy and their companion diagnostics, when appropriate, for patients with ovarian cancer in frontline maintenance, pretreated platinum-sensitive, pretreated platinum-refractory, and other settings, Plan strategies to prevent and/or manage the PARP inhibitor-associated adverse events, particularly in long-term use (eg, maintenance settings), in patients with ovarian cancer, Identify patients eligible for enrollment into clinical trials testing PARP inhibitors, including as combination approaches, in different treatment settings for ovarian cancer.